title: TNFR2 - target for therapeutics against neurodegenerative diseases?
authors.affiliation: Department of Molecular Neurobiology, University of Groningen, Groningen, The Netherlands. i.m.nijholt@med.umcg.nl
authors.forename: Ingrid M
authors.initials: IM
authors.lastname: Nijholt
authors.forename: Ivica
authors.initials: I
authors.lastname: Granic
authors.forename: Paul G M
authors.initials: PG
authors.lastname: Luiten
authors.forename: Ulrich L M
authors.initials: UL
authors.lastname: Eisel
mesh_terms: D000818:Animals; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D051379:Mice; D008954:Models, Biological; D019636:Neurodegenerative Diseases / Q000188:drug therapy*; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D051640:Small-Conductance Calcium-Activated Potassium Channels / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D018696:Neuroprotective Agents; D047889:Receptors, Tumor Necrosis Factor, Type II; D051640:Small-Conductance Calcium-Activated Potassium Channels; D014409:Tumor Necrosis Factor-alpha